Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 11 ( November, 2021 ) > List of Articles

Original Article

Management of Drug–Drug Interactions among Critically Ill Patients with Chronic Kidney Disease: Impact of Clinical Pharmacist's Interventions

Mina Aghili, Meera Neelathahalli Kasturirangan

Keywords : Chronic kidney disease, Clinical pharmacist's intervention, Critically ill patients, Drug–drug interaction

Citation Information : Aghili M, Kasturirangan MN. Management of Drug–Drug Interactions among Critically Ill Patients with Chronic Kidney Disease: Impact of Clinical Pharmacist's Interventions. Indian J Crit Care Med 2021; 25 (11):1226-1231.

DOI: 10.5005/jp-journals-10071-23919

License: CC BY-NC 4.0

Published Online: 16-11-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Background and objectives: Drug–drug interactions (DDIs) can create a burden on prescribers to preserve patient safety. This study aimed to identify common DDIs in critically ill patients with chronic kidney disease (CKD) and to evaluate clinical pharmacist's interventions in managing DDIs among these patients. Methods: A prospective observational study was conducted from October 2018 to March 2019. The clinical pharmacist performed a medication chart review; DDIs were identified by using Lexicomp® drug interaction. Based on the occurrence of DDIs, patients were divided into group A: patients with DDI (n = 76) and group B: patients without DDI (n = 15). Clinical pharmacist's interventions were classified according to Pharmaceutical Care Network Europe. The National Coordinating Council for Medication Error Reporting and Prevention was used to categorize the severity outcomes of DDIs and the degree of patient harm. Results: A total of 273 DDIs were identified. The majority of DDIs (63.7%) required close monitoring of the therapeutic outcome to ensure maintaining patient safety. DDIs that needed to be managed by considering therapy modification and avoiding drug combination were accounted for 17.2 and 12.8% of the most common detected interactions, respectively. Seventy-eight percent of DDIs induced no harm to patient. Clinical pharmacist provided different types of recommendations to manage detected interactions, which ranged from therapy outcome monitoring to stop DDIs. A great proportion of pharmacist's interventions (92%) were accepted by prescribers. Compared to patients with stage 3 and 4 CKD, patients with stage 5 had a significantly higher number of DDIs (stage 3 vs 5: p = 0.0019, stage 4 vs 5: p = 0.0456). The number of comorbidities (p = 0.0003) and (p <0.0001) medications were found to be significantly greater in group A. Conclusion: Clinical pharmacist performed important interventions in timely identifying, managing DDIs, and prevention of associated patient harms.

  1. Schoolwerth AC, Engelgau MM, Rufo KH, Vinicor F, Hostetter TH, Chianchiano D, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006;3:A57. DOI: 10.1053/j.ackd.2005.07.012.
  2. World Kidney Day. Chronic kidney disease 2015. Available from:
  3. Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol 2015;16:193. DOI: 10.1186/s12882-015-0189-z.
  4. Shippee ND, Shah ND, May CR, Mair FS, Montori VM. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol 2015;65(10):1041–1051. DOI: 10.1016/j.jclinepi.2012.05.005.
  5. Njeri LW, Ogallo WO, Nyamu DG, Opanga SA, Birichi AR. Medication-related problems among adult chronic kidney disease patients in a sub-Saharan tertiary hospital. Int J Clin Pharm 2018;40(5):1217–1224. DOI: 10.1007/s11096-018-0651-7.
  6. Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005;39(1):22–27. DOI: 10.1345/aph.1E269.
  7. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol 2018;13(7):1085–1095. DOI: 10.2215/CJN.00340118.
  8. Keller F, Hann A. Clinical pharmacodynamics: principles of drug response and alterations in kidney disease. Clin J Am Soc Nephrol 2018;13(9):1413–1420. DOI: 10.2215/CJN.10960917.
  9. American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy 2008;28(6):816–817. DOI: 10.1592/phco.28.6.816.
  10. Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997;47(2):117–121. PMID: 9049460
  11. Allenet B, Chen C, Romanet T, Vialtel P, Calop J. Assessing a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency. Pharm World Sci 2007;29(1):7–11. DOI: 10.1007/s11096-005-4800-4.
  12. Jiang SP, Zhu ZY, Wu XL, Lu XY, Zhang XG, Wu BH. Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study. Ther Clin Risk Manag 2014;10:405–412. DOI: 10.2147/TCRM.S59187.
  13. Moyen E, Camiré E, Stelfox HT. Clinical review: medication errors in critical care. Crit Care 2008;12(2):208. DOI: 10.1186/cc6813.
  14. Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug-drug interactions among renal failure patients of nephrology ward in a south Indian tertiary care hospital. Indian J Pharm Sci 2012;74(1):63–68. DOI: 10.4103/0250-474X.102545.
  15. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:A0828. HERO ID: 658418
  16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl. 1):S1–S266. PMID: 11904577
  17. Pharmaceutical Care Network Europe. Classification for drug related problems version 8.02, 2017. Available from:
  18. The National Coordinating Council for Medication Error Reporting and Prevention. NCC MERP index for categorizing medication errors. Available from:
  19. Marquito AB, Fernandes NM, Colugnati FA, de Paula RB. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol 2014;36(1):26–34. DOI: 10.5935/0101-2800.20140006.
  20. Saleem A, Masood I, Khan TM. Clinical relevancy and determinants of potential drug-drug interactions in chronic kidney disease patients: results from a retrospective analysis. Integr Pharm Res Pract 2017;6:71–77. DOI: 10.2147/IPRP.S128816.
  21. Fasipe OJ, Akhideno PE, Nwaiwu O, Adelosoye AA. Assessment of prescribed medications and pattern of distribution for potential drug-drug interactions among chronic kidney disease patients attending the Nephrology Clinic of Lagos University Teaching Hospital in Sub-Saharan West Africa. Clin Pharmacol 2017;9:125–132. DOI: 10.2147/CPAA.S147835.
  22. Mason NA, Bakus JL. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial 2010;23(1):55–61. DOI: 10.1111/j.1525-139X.2009.00629.x.
  23. McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, Dixon DL, et al. Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy 2015;35(4):e39–e50. DOI: 10.1002/phar.1563.
  24. Jorgenson D, Dalton D, Farrell B, Tsuyuki RT, Dolovich L. Guidelines for pharmacists integrating into primary care teams. Can Pharm J (Ott) 2013;146(6):342–352. DOI: 10.1177/1715163513504528.
  25. Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. Int J Clin Pharm 2019;41(3):630–666. DOI: 10.1007/s11096-019-00816-4.
  26. Jiang SP, Xu YY, Ping-Yang, Wu WF, Zhang XG, Lu XY, et al. Improving antimicrobial dosing in critically ill patients receiving continuous venovenous hemofiltration and the effect of pharmacist dosing adjustment. Eur J Intern Med 2014;25:930–935. DOI: 10.1016/j.ejim.2014.08.001.
  27. Ghaibi S, Ipema H, Gabay M. ASHP guidelines on the pharmacist's role in providing drug information. Am J Health Syst Pharm 2015;72(7):573–577. DOI: 10.2146/sp150002.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.